Extended Data Fig. 4: Chronic and acute effects of the NAD+ precursors on the urinary NAD+ metabolome.
Boxes ranging from the upper to the lower quartile with an indication of the median and the error bars represent the minimal and maximal values. Urine concentrations below LLOQ (Supplementary Table 2) were imputed with the LLOQ, and the number of data points is indicated below each treatment. a, Baseline concentrations of NAD+ precursors (blue), NAD+ degradation products (yellow) and NAR (green) in urine at visit 3 (V3, day 1) and at visit 4 (V4) after 14 days of daily consumption of either placebo, Nam, NR or NMN. Statistical significance of the differential changes compared to placebo is indicated (based on two-sided ANCOVA). b, Acute concentration changes of NAD+ precursors (blue), NAD+ degradation products (yellow) and NAR (green) in urine at V3 (day 1) over 4 h after consumption of either placebo, Nam, NR or NMN. Statistical significance of the differential changes compared to placebo is indicated (based on two-sided MMRM). * (0.05<P < 0.01), ** (0.01<P < 0.001), *** (P < 0.001).
